Oxyntomodulin

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 1, 2006, Pages 49-55

  Druce, Maralyn ^a,b   Ghatei, Mohammad ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Exendin 4; Food intake; Glucagon like peptide 1 (GLP 1); Oxyntomodulin

Indexed keywords

EXENDIN 4; GASTROINTESTINAL HORMONE; GLICENTIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; OXYNTOMODULIN;

BODY WEIGHT; CHEMICAL STRUCTURE; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; ENERGY BALANCE; ENERGY EXPENDITURE; EXOCRINE SECRETION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; INSULIN RELEASE; INTESTINE MOTILITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; STOMACH ACID SECRETION; STOMACH MUCOSA; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33646924270     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000200526.08653.bb     Document Type: Review

References (48)

1. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva, Switzerland: WHO; 1998.
2. Wynne K, Stanley S, McGowan B, et al. Appetite control. J Endocrinol 2005; 184:291-318. Comprehensive review discussing current understanding of the mechanisms regulating food intake and body weight, with particular focus on the gut hormones.
3. Bataille D, Coudray AM, Carlqvist M, et al. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Isolation of the peptide. FEBS Lett 1982; 146:73-78.
4. Bataille D, Gespach C, Coudray AM, et al. 'Enteroglucagon': a specific effect on gastric glands isolated from the rat fundus. Evidence for an 'oxyntomodulin' action. Biosci Rep 1981; 1:151-155.
5. Dubrasquet M, Bataille D, Gespach C. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep 1982; 2:391-395.
6. Jarrousse C, Bataille D, Jeanrenaud B. A pure enteroglucagon, oxyntomodulin (glucagon 37), stimulates insulin release in perfused rat pancreas. Endocrinology 1984; 115:102-105.
7. Jarrousse C, Audousset-Puech MP, Dubrasquet M, et al. Oxyntomodulin (glucagon-37) and its C-terminal octapeptide inhibit gastric acid secretion. FEBS Lett 1985; 188:81-84.
8. Schjoldager BT, Baldissera FG, Mortensen PE, et al. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 1988; 18:499-503.
9. Schjoldager B, Mortensen PE, Myhre J, et al. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 1989; 34:1411-1419.
10. Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001; 142:4244-4250.
11. Dakin CL, Small CJ, Park AJ, et al. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 2002; 283:E1173-E1177.
12. Dakin CL, Small CJ, Batterham RL, et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145:2687-2695.
13. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88:4696-4701.
14. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54:2390-2395. Important recent randomized controlled trial of subcutanous, preprandial administration of oxyntomodulin three times daily showing a significant weight loss in treated subjects over 4 weeks. There were no significant effects on blood glucose (unlike with GLP-1 and exendin 4) and the treatment was well tolerated.
15. Blache P, Kervran A, Bataille D. Oxyntomodulin and glicentin: brain-gut peptides in the rat. Endocrinology 1988; 123:2782-2787.
16. Holst JJ, Enteroglucagon. Annu Rev Physiol 1997; 59:257-271.
17. Ghatei MA, Uttenthal LO, Christofides ND, et al. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 1983; 57:488-495.
18. Le Quellec A, Kervran A, Blache P, et al. Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. J Clin Endocrinol Metab 1992; 74:1405-1409.
19. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214:829-835.
20. Zhu L, Tamvakopoulos C, Xie D, et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 2003; 278:22418-22423.
21. Besterman HS, Cook GC, Sarson DL, et al. Gut hormones in tropical malabsorption. Br Med J 1979; 2:1252-1255.
22. Holst JJ, Sorensen TI, Andersen AN, et al. Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Scand J Gastroenterol 1979; 14:205-207.
23. Sarson DL, Scopinaro N, Bloom SR. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 1981; 5:471-480.
24. Naslund E, King N, Mansten S, et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004; 91:439-446.
25. Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005; 7:467-477. Short randomized controlled trial of exendin-4 as a potential treatment for type 2 diabetes, demonstrating its ability to reduce blood sugar. It also led to a significant reduction in body weight which was dose-dependent. Nausea was, however, a troublesome side-effect.
26. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092-1100. Prolonged randomized controlled trial of exendin-4 as a potential treatment for type 2 diabetes, demonstrating its ability to reduce blood sugar. Again there was a significant reduction in body weight which was dose-dependent.
27. Baggio LL, Huang Q, Brown TJ, et al. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127:546-558. An important paper examining the effects of OXM and GLP-1 in mice. The absence of effects of OXM in GLP-1 knockout mice suggests a mode of action via the GLP-1 receptor, but the two peptides had differential effects, suggesting possible downstream modulation of activity.
28. Jarrousse C, Carles-Bonnet C, Niel H, et al. Inhibition of gastric acid secretion by oxyntomodulin and its 19-37 fragment in the conscious rat. Am J Physiol 1993; 264:G816-G823.
29. Carles-Bonnet C, Martinez J, Jarrousse C, et al. H-Lys-Arg-Asn-Lys-Asn- Asn-OH is the minimal active structure of oxyntomodulin. Peptides 1996; 17:557-561.
30. Jarrousse C, Niel H, Audousset-Puech MP, et al. Oxyntomodulin and its C-terminal octapeptide inhibit liquid meal-stimulated acid secretion. Peptides 1986; 7 (Suppl 1):253-256.
31. Anini Y, Jarrousse C, Chariot J, et al. Oxyntomodulin inhibits pancreatic secretion through the nervous system in rats. Pancreas 2000; 20:348-360.
32. Gehl J, Jeppesen JL, Poulsen SS, et al. The gastric acid secretagogue gastrin-releasing peptide and the inhibitor oxyntomodulin do not exert their effect directly on the parietal cell in the rat. Digestion 1988; 40:144-151.
33. Schepp W, Dehne K, Riedel T, et al. Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2. Digestion 1996; 57:398-405.
34. Gros L, Demirpence E, Jarrousse C, et al. Characterization of binding sites for oxyntomodulin on a somatostatin-secreting cell line (RIN T3). Endocrinology 1992; 130:1263-1270.
35. Tani T, Le Quellec A, Jarrousse C, et al. Oxyntomodulin and related peptides control somatostatin secretion in RIN T3 cells. Biochim Biophys Acta 1991; 1095:249-254.
36. Dubrasquet JM, Audousset-Puech MP, Martinez J, et al. Somatostatin enhances the inhibitory effect of oxyntomodulin and its C-terminal octapeptide on acid secretion. Peptides 1986; 7 (Suppl 1):257-259.
37. Beauclair F, Eto B, Pansu D, et al. Oxyntomodulin reduces hydromineral transport through rat small intestine. Dig Dis Sci 1998; 43:1814-1823.
38. Biedzinski TM, Bataille D, Devaux MA, et al. The effect of oxyntomodulin (glucagon-37) and glucagon on exocrine pancreatic secretion in the conscious rat. Peptides 1987; 8:967-972.
39. Rodier G, Magous R, Mochizuki T, et al. Effect of glicentin, oxyntomodulin and related peptides on isolated gastric smooth muscle cells. Pflugers Arch 1997; 434:729-734.
40. Rodier G, Magous R, Mochizuki T, et al. A target cell to oxyntomodulin and glicentin: the antral smooth muscle cell. Ann N Y Acad Sci 1998; 865:458-462.
41. Rodier G, Magous R, Mochizuki T, et al. Glicentin and oxyntomodulin modulate both the phosphoinositide and cyclic adenosine monophosphate signaling pathways in gastric myocytes. Endocrinology 1999; 140:22-28.
42. Pellissier S, Sasaki K, Le Nguyen D, et al. Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine. Neurogastroenterol Motil 2004; 16:455-463. In vivo studies looking at the myoelectric effects of OXM on the smooth muscle of the stomach and small intestine, demonstrating the clear effects of the peptide on gut motility.
43. Baldissera FG, Holst JJ, Knuhtsen S, et al. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept 1988; 21:151-166.
44. Schmidtler J, Dehne K, Allescher HD, et al. Rat parietal cell receptors for GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding. Am J Physiol 1994; 267:G423-G432.
45. Fehmann HC, Jiang J, Schweinfurth J, et al. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides 1994; 15:453-456.
46. Gros L, Thorens B, Bataille D, Kervran A. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 1993; 133:631-638.
47. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379:69-72.
48. Carles-Bonnet C, Jarrousse C, Niel H, et al. N-acetyl oxyntomodulin30-37: pharmacokinetics and activity on gastric acid secretion. Naunyn Schmiedebergs Arch Pharmacol 1992; 345:57-63.